Alcresta selected StayinFront's life sciences CRM solution for its breadth of specialized functionality, including sophisticated targeting, call tracking and sample tracking tools, as well as integrated analytics and KPIs. These tools, along with the advanced closed loop marketing (CLM) tool, StayinFront PitchBook Rx™, will ensure field reps have all the information they need to effectively manage their territories and engage healthcare professionals with rich, relevant presentations.

"We have an innovative product and were looking for a company that could deliver a mobile system to help our field based reps work more efficiently and effectively," stated Steve Parsons, Vice President of Sales at Alcresta Pharmaceuticals. "StayinFront's experience in life sciences industry and ability to rapidly deploy a, a leading edge mobile cloud-based solution made this an easy choice for us."

"We are pleased to be partnering with Alcresta and are committed to delivering world-class products and services," commented Ken Arbadji, VP of North American Sales at StayinFront. "TouchRx will deliver the tools Alcresta and their field team need to do more, know more and successfully grow their business."

About StayinFrontStayinFront is a leading global provider of mobile, cloud-based field force effectiveness and customer relationship management solutions for consumer goods and life sciences organizations. Companies of all sizes in over 50 countries use StayinFront software to streamline sales operations and reduce the complexity, time and expense associated with field efforts. StayinFront products provide companies with timely, accurate field data and insight, enabling field reps and management to do more, know more and sell more. Headquartered in Fairfield, NJ, USA, StayinFront has offices in Chicago, the United Kingdom, Turkey, Ireland, India, Australia, Singapore and New Zealand. For more details visit http://stayinfront.com

About Alcresta Pharmaceuticals Alcresta is a specialty pharmaceutical company dedicated to developing and commercializing novel enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth and other serious diseases. The company's lead product, Relizorb™, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). For more information about Alcresta Pharmaceuticals or its products, visit alcresta.com